Bronchodilator combination therapy for the treatment of chronic obstructive pulmonary disease

Current Clinical Pharmacology

Volumn 6, Issue 1, 2011, Pages 48-61

  Sethi, Sanjay ^a,b   Cote, Claudia ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA Western New York Health Care System   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Anticholinergics; Bronchodilator combination therapy; Chronic obstructive pulmonary disease; Long acting 2 adrenergic receptor agonist

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 79953062757     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488411794941331     Document Type: Review

References (48)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2008: Available from: http://www.goldcopd.com/Guidelineitem.asp?11=2&12=1&intId=989.
2. American Lung Association. 2010: Available from: http://-www.lungusa.org/lung-disease/copd/.
3. Curtis JR, Patrick DL. The assessment of health status among patients with COPD. Eur Respir J Suppl 2003; 41: 36s-45s.
4. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006; 28(6): 1245-57.
5. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6): 932-46.
6. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease. Can Respir J 2003; (10 Suppl A): 11A-65A.
7. Colice GL, Carnathan B, Sung J, Paramore LC. A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator. J Asthma 2005; 42(1): 29-34.
8. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19(5): 936-43.
9. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6): 912-9.
10. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(5): 778-84.
11. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slowrelease theophylline in the treatment of COPD. Chest 2002; 121(4): 1058-69.
12. Wadbo M, Lofdahl CG, Larsson K, et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 2002; 20(5): 1138-46.
13. Sichletidis L, Kottakis J, Marcou S, Constantinidis TC, Antoniades A. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999; 53(3): 185-8.
14. Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004; 17(1): 35-9.
15. Richter K, Stenglein S, Mucke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006; 73(4): 414-9.
16. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26(2): 214-22.
17. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15(5): 878-85.
18. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995; 50(7): 750-4.
19. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(5):1087-92.
20. Mahler DA. The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002; 110(6 Suppl): S298-303.
21. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115(4): 957-65.
22. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155(4): 1283-9.
23. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356): 449-56.
24. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166(8): 1084-91.
25. Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of the bronchodilating effects of salmeterol, albuterol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995; 8(6): 267-71.
26. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122(1): 47-55.
27. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58(5): 399-404.
28. Briggs DD, Jr., Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005; 18(6): 397-404.
29. Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc 2004; 1(4): 345-51.
30. Rennard SI. Combination bronchodilator therapy in COPD. Chest 1995; 107(5 Suppl): 171S-5S.
31. Watson N, Eglen RM. Effects of muscarinic M2 and M3 receptor stimulation and antagonism on responses to isoprenaline of guineapig trachea in vitro. Br J Pharmacol 1994; 112(1): 179-87.
32. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105(5): 1411-9.
33. Levin DC, Little KS, Laughlin KR, et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Am J Med 1996; 100(1A): 40S-8S.
34. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999; 159(2): 156-60.
35. Cazzola M, Di Perna F, Califano C, Vinciguerra A, D'Amato M. Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD. Pulm Pharmacol Ther 1999; 12(4): 267-71.
36. Cazzola M, Di Perna F, Centanni S, et al. Acute effect of pretreatment with single conventional dose of salmeterol on doseresponse curve to oxitropium bromide in chronic obstructive pulmonary disease. Thorax 1999; 54(12): 1083-6.
37. Cazzola M, Matera MG, Di Perna E, Califano C, D'Amato M, Mazzarella G. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respir Med 1999; 93(12): 909-11.
38. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of albuterol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001; 119(5): 1347-56.
39. Cazzola M, Centanni S, Santus P, et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004; 98(12): 1214-21.
40. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129(3): 509-17.
41. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134(2): 255-62.
42. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009; 6(1): 17-25.
43. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146(8): 545-55.
44. Rennard SI, Stoner JA. Challenges and opportunities for combination therapy in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2(4): 391-3; discussion 4-5.
45. Cooper CB, Tashkin DP. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330(7492): 640-4.
46. Koul PA. Managing chronic diseases: combination of inhaler treatment in India has shown good results. BMJ 2005; 330(7497): 964; discussion -5.
47. Tennant RC, Erin EM, Barnes PJ, Hansel TT. Long-acting beta 2- adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified? Curr Opin Pharmacol 2003; 3(3): 270-6.
48. Cazzola M, Matera MG, D'Amato M, et al. Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. Pulm Pharmacol Ther 2003; 16(2): 105-9.